1. Home
  2. NUVB vs RYI Comparison

NUVB vs RYI Comparison

Compare NUVB & RYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NUVB
  • RYI
  • Stock Information
  • Founded
  • NUVB 2018
  • RYI 1842
  • Country
  • NUVB United States
  • RYI United States
  • Employees
  • NUVB N/A
  • RYI N/A
  • Industry
  • NUVB Biotechnology: Pharmaceutical Preparations
  • RYI Metal Fabrications
  • Sector
  • NUVB Health Care
  • RYI Industrials
  • Exchange
  • NUVB Nasdaq
  • RYI Nasdaq
  • Market Cap
  • NUVB 837.0M
  • RYI 699.3M
  • IPO Year
  • NUVB N/A
  • RYI N/A
  • Fundamental
  • Price
  • NUVB $3.89
  • RYI $23.48
  • Analyst Decision
  • NUVB Strong Buy
  • RYI Hold
  • Analyst Count
  • NUVB 6
  • RYI 1
  • Target Price
  • NUVB $8.00
  • RYI $25.00
  • AVG Volume (30 Days)
  • NUVB 6.2M
  • RYI 197.0K
  • Earning Date
  • NUVB 11-05-2025
  • RYI 10-28-2025
  • Dividend Yield
  • NUVB N/A
  • RYI 3.19%
  • EPS Growth
  • NUVB N/A
  • RYI N/A
  • EPS
  • NUVB N/A
  • RYI N/A
  • Revenue
  • NUVB $14,355,000.00
  • RYI $4,439,000,000.00
  • Revenue This Year
  • NUVB $332.80
  • RYI $0.42
  • Revenue Next Year
  • NUVB $360.12
  • RYI $3.36
  • P/E Ratio
  • NUVB N/A
  • RYI N/A
  • Revenue Growth
  • NUVB 900.35
  • RYI N/A
  • 52 Week Low
  • NUVB $1.54
  • RYI $17.18
  • 52 Week High
  • NUVB $4.09
  • RYI $27.41
  • Technical
  • Relative Strength Index (RSI)
  • NUVB 83.37
  • RYI 61.26
  • Support Level
  • NUVB $2.87
  • RYI $21.80
  • Resistance Level
  • NUVB $3.08
  • RYI $22.99
  • Average True Range (ATR)
  • NUVB 0.22
  • RYI 0.64
  • MACD
  • NUVB 0.08
  • RYI 0.10
  • Stochastic Oscillator
  • NUVB 86.52
  • RYI 89.32

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.

About RYI Ryerson Holding Corporation

Ryerson Holding Corp provides a metals service center, and value-added processor and is a distributor of industrial metals with operations in the United States, Canada, and Mexico. In addition to its North American operations, it conducts processing and distribution operations in China. Its customers range from local, independently owned fabricators and machine shops to large, international original equipment manufacturers. It carries a full line of products in stainless steel, aluminum, carbon steel, and alloy steels and a limited line of nickel and red metals in various shapes and forms. The company generates substantially all of its revenue from sales of metal products. Geographically, the majority revenue is generated from the United States.

Share on Social Networks: